First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice

Peer Exchange

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

Patients With Intermediate Stage HCC Unsuitable for TACE

Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

Patients With Intermediate Stage HCC Suitable for TACE

HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

Selecting the Appropriate Frontline Treatment in Advanced HCC

Other Frontline Immunotherapy-based Combinations in Advanced HCC

Patient Profile 2: Advanced HCC Treated with Lenvatinib

Real-World Evidence for Lenvatinib in Advanced HCC

Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

Treatment Considerations for Advanced HCC in Second Line and Beyond

Management of Child-Pugh B Patients with Advanced HCC

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023